Compare BELFB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | IDYA |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 1994 | 2019 |
| Metric | BELFB | IDYA |
|---|---|---|
| Price | $242.65 | $39.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $174.25 | $52.86 |
| AVG Volume (30 Days) | 150.6K | ★ 701.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,611,000.00 | $218,710,000.00 |
| Revenue This Year | $9.74 | N/A |
| Revenue Next Year | $6.34 | $201.05 |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $129.94 | $23.23 |
| 52 Week High | $335.29 | $42.68 |
| Indicator | BELFB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 58.13 |
| Support Level | $219.03 | $33.57 |
| Resistance Level | $248.61 | $39.93 |
| Average True Range (ATR) | 10.61 | 1.35 |
| MACD | -3.11 | 0.09 |
| Stochastic Oscillator | 3.26 | 59.26 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.